As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.